[Study on immunogenicity of group A and group C meningococcal conjugate vaccine with coupling group B meningococcal outer membrane protein].
OBJECTIVE
To evaluate the Immunogenicity of Group A and Group C Meningococcal conjugate Vaccine with coupling Group B Meningococcal Outer Membrane Protein (Men B-OMP).


METHODS
458 healthy children aged 3-5 months, 6-23 months, 2-6 years and 7-24 years were given the Groups A and C conjugate Vaccine with MenB-OMP or other vaccine as control group to measure the pre-and post-vaccination Men A and C and B by Serum Bactericidal Assay (SBA) in the double-blind randomized controlled trial.


RESULTS
97.65%-100% were 4 times or greater increase in SBA titer for the healthy children given the Groups A and C conjugate Vaccine with MenB-OMP, The geometric mean titer of SBA were 1:194-1:420, which significantly higber than controls.


CONCLUSIONS
The Group A and C conjugate Vaccine with MenB-OMP was safe and well immunogenic.
Ma
Fu-Bao
FB
Jiangsu Province Center for Disease Control and Prevention, Nanjing 210009, Jiangsu, China.
Tao
Hong
H
Wang
Hong-Jun
HJ
D000293:Adolescent; D001425:Bacterial Outer Membrane Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008585:Meningitis, Meningococcal / Q000276:immunology* / Q000382:microbiology; D022401:Meningococcal Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D038381:Neisseria meningitidis, Serogroup A / Q000276:immunology; D038541:Neisseria meningitidis, Serogroup B / Q000276:immunology; D038542:Neisseria meningitidis, Serogroup C / Q000276:immunology; D018074:Vaccines, Conjugate / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D055815:Young Adult
D001425:Bacterial Outer Membrane Proteins; D022401:Meningococcal Vaccines; D018074:Vaccines, Conjugate